- Record: found
- Abstract: found
- Article: not found
Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs.
Jia-Jia Huang
1 ,
Zhi-Ming Li ,
Ying Huang ,
Yan Huang ,
Ying Tian ,
Xue-Xin He ,
Jian Xiao ,
Tong-Yu Lin
Feb 2012
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Everolimus (RAD001) is a novel mammalian target of rapamycin (mTOR) inhibitor, and anti-proliferative activity in various malignancies has been reported. This study evaluated the anti-tumor effects and schedule-dependent synergism of everolimus in combination with other chemotherapeutic agents in T-cell lymphoma cell lines.